Mattrey R F, Trambert M A, Brown J J, Young S W, Bruneton J N, Wesbey G E, Balsara Z N
Department of Radiology, University of California, San Diego.
Radiology. 1994 Jun;191(3):841-8. doi: 10.1148/radiology.191.3.8184076.
To assess perflubron for magnetic resonance (MR) imaging in the abdomen and pelvis in a multicenter trial.
MR images were obtained in 127 subjects before and after ingestion of perflubron with T1-, proton-density-, and T2-weighted sequences at 0.38, 1.0, or 1.5 T. Postcontrast images were compared with baseline images, and percentage of additional bowel darkened, distinction of bowel from adjacent tissue, and change in image artifact were graded.
Perflubron increased the bowel darkening in over 92% of subjects with all sequences and field strengths. It improved definition of the left lobe of the liver and body and tail of the pancreas in 67%, 29%, and 42% of subjects, respectively, and of the uterus and bladder in 80% and 76%. Abnormal tissue was more conspicuous in 69% of subjects. Highest scores were achieved when the upper abdomen was imaged 5-30 minutes and the pelvis 10-40 minutes after ingestion. No image artifacts or side effects were attributed to perflubron.
Perflubron is safe, and its efficacy was unaffected by pulse sequences, magnetic field strength, or time delay.
在一项多中心试验中评估全氟溴辛烷用于腹部和骨盆的磁共振（MR）成像。
127名受试者在摄入全氟溴辛烷前后，使用0.38、1.0或1.5T的T1加权、质子密度加权和T2加权序列获取MR图像。将增强后图像与基线图像进行比较，并对肠管额外变黑的百分比、肠管与相邻组织的区分以及图像伪影的变化进行分级。
在所有序列和场强下，超过92%的受试者使用全氟溴辛烷后肠管变黑增加。分别有67%、29%和42%的受试者肝脏左叶、胰腺体部和尾部以及80%和76%的受试者子宫和膀胱的清晰度得到改善。69%的受试者中异常组织更明显。摄入后5 - 30分钟对上腹部成像，10 - 40分钟对骨盆成像时得分最高。未发现全氟溴辛烷导致的图像伪影或副作用。
全氟溴辛烷是安全的，其疗效不受脉冲序列、磁场强度或时间延迟的影响。
